Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
How does the micro-cap biotech now finance a 700-patient phase 3 study?